These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 1319390)

  • 1. Diffuse and localized tenosynovial giant cell tumor and pigmented villonodular synovitis: a clinicopathologic and flow cytometric DNA analysis.
    Abdul-Karim FW; el-Naggar AK; Joyce MJ; Makley JT; Carter JR
    Hum Pathol; 1992 Jul; 23(7):729-35. PubMed ID: 1319390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis/tenosynovial giant cell tumor in the knee joints.
    Kim DE; Kim JM; Lee BS; Kim NK; Lee SH; Bin SI
    Knee Surg Sports Traumatol Arthrosc; 2018 Nov; 26(11):3508-3514. PubMed ID: 29637236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
    Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB
    Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of Illness Associated with Tenosynovial Giant Cell Tumors.
    Burton TM; Ye X; Parker ED; Bancroft T; Healey J
    Clin Ther; 2018 Apr; 40(4):593-602.e1. PubMed ID: 29580718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence.
    Martin RC; Osborne DL; Edwards MJ; Wrightson W; McMasters KM
    Oncol Rep; 2000; 7(2):413-9. PubMed ID: 10671695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.
    Palmerini E; Staals EL; Maki RG; Pengo S; Cioffi A; Gambarotti M; Picci P; Daolio PA; Parafioriti A; Morris C; Antonescu CR; Gronchi A; Casali PG; Donati DM; Ferrari S; Stacchiotti S
    Eur J Cancer; 2015 Jan; 51(2):210-7. PubMed ID: 25465190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pigmented villonodular synovitis (giant-cell tumor of the tendon sheath and synovial membrane). A review of eighty-one cases.
    Rao AS; Vigorita VJ
    J Bone Joint Surg Am; 1984 Jan; 66(1):76-94. PubMed ID: 6317696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pigmented Villonodular Synovitis - Various Manifestations, Inconsistent Terminology and Treatment. Cases Study.
    Kokoszka P; Woźniak W; Łapaj Ł; Kruczyński J
    Ortop Traumatol Rehabil; 2017 Jan; 19(1):79-88. PubMed ID: 28436371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid arthritis and pigmented villonodular synovitis: comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells.
    Berger I; Weckauf H; Helmchen B; Ehemann V; Penzel R; Fink B; Bernd L; Autschbach F
    Histopathology; 2005 May; 46(5):490-7. PubMed ID: 15842630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Tenosynovial Giant Cell Tumor of the Foot and Ankle.
    Barnett JR; Rudran B; Khan A; O'Reilly-Harbidge S; Patel S; Malhotra K; Cullen N; Welck M; Aston W
    Foot Ankle Int; 2023 Oct; 44(10):1013-1020. PubMed ID: 37644900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
    Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY
    Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal pigmented villonodular synovitis and tenosynovial giant cell tumor: A report of two cases and a comprehensive systematic review.
    Zeoli T; Mathkour M; Scullen T; Carr C; Abou-Al-Shaar H; Wang L; Divagaran A; Dindial R; Tubbs RS; Bui CJ; Maulucci CM
    Clin Neurol Neurosurg; 2021 Mar; 202():106489. PubMed ID: 33596487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
    Ravi V; Wang WL; Lewis VO
    Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologically benign metastasizing tenosynovial giant cell tumor mimicking metastatic malignancy: A case report and review of literature.
    Chen EL; de Castro CM; Hendzel KD; Iwaz S; Kim MA; Valeshabad AK; Shokouh-Amiri M; Xie KL
    Radiol Case Rep; 2019 Aug; 14(8):934-940. PubMed ID: 31193787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease.
    Somerhausen NS; Fletcher CD
    Am J Surg Pathol; 2000 Apr; 24(4):479-92. PubMed ID: 10757395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
    Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
    Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life.
    Mastboom MJ; Planje R; van de Sande MA
    Interact J Med Res; 2018 Feb; 7(1):e4. PubMed ID: 29475829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
    West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.